Protalix BioTherapeutics (PLX) Competitors $1.70 +0.04 (+2.42%) (As of 11/22/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PLX vs. ZVRA, ESPR, TERN, KRRO, MGTX, ARCT, RGNX, XERS, YMAB, and AURAShould you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include Zevra Therapeutics (ZVRA), Esperion Therapeutics (ESPR), Terns Pharmaceuticals (TERN), Korro Bio (KRRO), MeiraGTx (MGTX), Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), Xeris Biopharma (XERS), Y-mAbs Therapeutics (YMAB), and Aura Biosciences (AURA). These companies are all part of the "pharmaceutical products" industry. Protalix BioTherapeutics vs. Zevra Therapeutics Esperion Therapeutics Terns Pharmaceuticals Korro Bio MeiraGTx Arcturus Therapeutics REGENXBIO Xeris Biopharma Y-mAbs Therapeutics Aura Biosciences Protalix BioTherapeutics (NYSE:PLX) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, community ranking, earnings, valuation and analyst recommendations. Is PLX or ZVRA more profitable? Protalix BioTherapeutics has a net margin of -21.03% compared to Zevra Therapeutics' net margin of -342.63%. Protalix BioTherapeutics' return on equity of -30.89% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Protalix BioTherapeutics-21.03% -30.89% -11.74% Zevra Therapeutics -342.63%-159.54%-51.50% Do analysts prefer PLX or ZVRA? Zevra Therapeutics has a consensus target price of $21.00, suggesting a potential upside of 119.09%. Given Zevra Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Zevra Therapeutics is more favorable than Protalix BioTherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Does the media favor PLX or ZVRA? In the previous week, Zevra Therapeutics had 33 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 34 mentions for Zevra Therapeutics and 1 mentions for Protalix BioTherapeutics. Zevra Therapeutics' average media sentiment score of 0.19 beat Protalix BioTherapeutics' score of -0.34 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Protalix BioTherapeutics Neutral Zevra Therapeutics Neutral Which has preferable earnings & valuation, PLX or ZVRA? Protalix BioTherapeutics has higher revenue and earnings than Zevra Therapeutics. Protalix BioTherapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProtalix BioTherapeutics$65.49M1.91$8.31M-$0.13-13.04Zevra Therapeutics$27.46M18.63-$46.05M-$1.97-4.87 Does the MarketBeat Community believe in PLX or ZVRA? Zevra Therapeutics received 23 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. Likewise, 100.00% of users gave Zevra Therapeutics an outperform vote while only 66.67% of users gave Protalix BioTherapeutics an outperform vote. CompanyUnderperformOutperformProtalix BioTherapeuticsOutperform Votes666.67% Underperform Votes333.33% Zevra TherapeuticsOutperform Votes29100.00% Underperform VotesNo Votes Which has more volatility and risk, PLX or ZVRA? Protalix BioTherapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.93, suggesting that its stock price is 93% more volatile than the S&P 500. Do insiders & institutionals believe in PLX or ZVRA? 16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 6.3% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryZevra Therapeutics beats Protalix BioTherapeutics on 12 of the 19 factors compared between the two stocks. Ad Darwin2024 Election Year Stocks: Uncover Hidden Gems!In the lead-up to the pivotal 2024 election year, we're excited to present our comprehensive report, "Election Year Investment Gems: Stock Poised To Takeoff In 2024," brimming with insights and opportunities you won't want to miss.Secure your copy now by clicking this link. Get Protalix BioTherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLX vs. The Competition Export to ExcelMetricProtalix BioTherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$124.80M$3.04B$5.38B$20.16BDividend YieldN/A1.91%5.13%3.50%P/E Ratio-13.0445.50105.9744.53Price / Sales1.91392.401,243.8117.75Price / Cash11.94169.3840.2921.28Price / Book3.854.597.084.71Net Income$8.31M-$41.63M$119.58M$986.85M7 Day Performance21.07%2.62%2.25%3.76%1 Month Performance66.18%-2.46%-2.33%4.65%1 Year Performance20.21%28.25%33.91%27.69% Protalix BioTherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLXProtalix BioTherapeuticsN/A$1.70+2.4%N/A+20.2%$124.80M$65.49M-13.04200ZVRAZevra Therapeutics3.4837 of 5 stars$9.13+1.8%$21.00+130.0%+115.9%$487.36M$27.46M-4.6965Analyst ForecastAnalyst RevisionNews CoverageESPREsperion Therapeutics3.9468 of 5 stars$2.47+2.5%$8.17+230.6%+108.3%$486.69M$116.33M-3.77240Analyst ForecastTERNTerns Pharmaceuticals4.339 of 5 stars$5.71+2.0%$27.25+377.2%+58.6%$485.01M$1M-4.8440News CoverageKRROKorro Bio2.7334 of 5 stars$50.62+7.7%$142.17+180.9%+38.1%$474.31M$14.07M0.0070Analyst ForecastNews CoverageGap UpMGTXMeiraGTx4.3062 of 5 stars$5.92+1.7%$23.50+297.0%+9.6%$462.65M$14.02M-4.89300ARCTArcturus Therapeutics2.4974 of 5 stars$17.06+5.5%$71.40+318.5%-28.1%$462.16M$169.93M-7.28180RGNXREGENXBIO4.4572 of 5 stars$9.18-4.7%$35.27+284.2%-49.9%$454.78M$90.24M-1.83344Analyst ForecastAnalyst RevisionNews CoverageXERSXeris Biopharma3.7797 of 5 stars$3.04-0.7%$4.87+60.1%+77.6%$453.20M$163.91M-6.76290YMABY-mAbs Therapeutics3.14 of 5 stars$10.10-4.2%$21.38+111.6%+91.0%$452.38M$84.82M-18.70150AURAAura Biosciences3.5219 of 5 stars$8.98+2.6%$23.00+156.1%+12.2%$448.55MN/A-5.0650High Trading Volume Related Companies and Tools Related Companies Zevra Therapeutics Alternatives Esperion Therapeutics Alternatives Terns Pharmaceuticals Alternatives Korro Bio Alternatives MeiraGTx Alternatives Arcturus Therapeutics Alternatives REGENXBIO Alternatives Xeris Biopharma Alternatives Y-mAbs Therapeutics Alternatives Aura Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PLX) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protalix BioTherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protalix BioTherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
